Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.74 |
| ▸ | HPGD | P15428 | 5/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7929987 | 0.86 | NPC1 (0.63) | KDM4EALDH1A1HPGDGAAKMT2A | |
| SCHEMBL27804582 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1HPGDHDAC1HDAC2 | |
| SCHEMBL23932897 | 0.84 | KDM4E (0.76) | KDM4EALDH1A1HPGDHDAC1HDAC2 | |
| SCHEMBL7925080 | 0.84 | HDAC1 (0.71) | KDM4EALDH1A1HPGDHDAC1HDAC2 | |
| SCHEMBL7930408 | 0.84 | HDAC1 (0.67) | KDM4EALDH1A1HPGDHDAC1HDAC2 | |
| SCHEMBL13357164 | 0.81 | ALDH1A1 (0.70) | KDM4EALDH1A1HPGDHDAC1HDAC2 | |
| SCHEMBL13357176 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HPGDHDAC1HDAC2 | |
| SCHEMBL7933652 | 0.80 | SMN1; SMN2 (0.71) | KDM4EALDH1A1HPGDHDAC1HDAC2 | |
| SCHEMBL13357165 | 0.79 | KDM4E (0.67) | KDM4EALDH1A1HPGDHDAC1HDAC2 | |
| SCHEMBL13357690 | 0.79 | KDM4E (0.70) | KDM4EALDH1A1HPGDHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | KDM4E 1274/4885ALDH1A1 496/4885HPGD 194/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | KDM4E 1963/4885ALDH1A1 2213/4885HPGD 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.